Liver function may change how mavorixafor works in the body

NCT ID NCT06858696

Completed Knowledge-focused Sponsor: X4 Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates how a single dose of mavorixafor is processed in people with mild to moderate liver impairment compared to healthy volunteers with normal liver function. Researchers will measure drug levels in the blood and monitor safety and tolerability. The goal is to understand whether liver problems affect how the body handles mavorixafor, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavorixafor
What this could lead to: If successful, this study could help determine safe and effective dosing of mavorixafor for people with liver impairment.
What could go wrong: This is an early-phase study with only 39 participants, so results may not apply to everyone. Liver impairment can unpredictably alter drug processing, and safety findings are preliminary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY

Contacts and locations

Show contact details

Locations

Catalina Research Institute, LLC

Montclair, California, 91763, United States
Catalina Research Institute, LLC

Rialto, California, 91763, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Texas Liver Institute/Alamo Medical Research

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.